Is ORIC Pharmaceuticals, Inc. (ORIC) a Buy, Sell, or Hold?
NASDAQ : ORIC
ORIC Pharmaceuticals, Inc.
$12.1 USD
$1.21 (11.11%)
- Volume
- 3.61M
- Average Volume
- 1.62M
- Market Capitalization
- $1.25B
- P/E Ratio
- -8.40
- Dividend Yield
- 0.00%
- Price Target
- $15.00
- Year High
- $14.93
- Year Low
- $7.23
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $16.33
Company Overview
NASDAQ
Jacob Chacko
Biotechnology
Healthcare
ORIC
104
US
USD
Liquidity Metrics
0.01
16.33
16.33
3.17
0.00
Sales & Valuation
-$
0.00
3.07
-11.25
-1.06
Profitability
-$1.47
-$129.47M
0.00%
0.00%
-35.33%
-30.96%
P/E Metrics
-8.40
-0.32
-0.32
Analyst Price Target & Rating
$15.00
$25.00
$15.00
2/5
10 Analysts
-19.33%
Financial Health Scores
32.83
2/9
$272.46M
$436.76M
$21.2M
-$135.21M
Key Metrics (TTM)
$1.2B
0.00
-8.95
16.33
-35.33%
-35.50%
-10.59%
-8.89%
-3302 days
Company Executives
| Name | Title |
|---|---|
| Scott W. Lowe | Founder & Member of Scientific Advisory Board |
| Jacob Chacko | President, Chief Executive Officer & Director |
| Kevin Brodbeck | Chief Technical Officer |
| Richard A. Heyman | Founder, Independent Chairman & Member of Scientific Advisory Board |
| Daniel Iazzetti | Vice President & Head of People |
| Dominic G. Piscitelli | Chief Financial Officer |
| Christian V. Kuhlen | General Counsel |
| Pratik S. Multani | Chief Medical Officer |
| Charles L. Sawyers | Founder & Member of Scientific Advisory Board |
| Lori Sickels Friedman | Chief Scientific Officer |
Poll Results
No votes yet today — be the first to share your view!
About ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Stock
ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates. ORIC-533 is an oral small molecule designed to inhibit CD73, addressing resistance to both chemotherapy and immunotherapy. Another candidate, ORIC-944, is an allosteric inhibitor targeting the polycomb repressive complex 2, specifically for the treatment of prostate cancer. Furthermore, ORIC-114 is a brain-penetrant, orally administered, irreversible inhibitor crafted to precisely target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), demonstrating high potency against exon 20 insertion m ... utations. Beyond these advanced programs, ORIC Pharmaceuticals is also cultivating multiple early-stage precision medicines aimed at other mechanisms of cancer resistance. The company has established partnerships, including a licensing and collaboration agreement with Voronoi Inc., and a licensing agreement with Mirati Therapeutics, Inc. ORIC Pharmaceuticals was founded in 2014 and maintains its headquarters in South San Francisco, California.
ORIC Pharmaceuticals: Royalty-Free Phase 3 Economics Strengthen The Bull Case
2026-07-21 10:30:45
ORIC Pharmaceuticals advances rinzimetostat into the global Phase 3 Himalayas-1 trial for mCRPC, with full global rights and royalty-free economics. ORIC's $419.7M cash position funds operations into 2H 2028, supporting pivotal trial readouts while minimizing dilution via strategic partnerships and disciplined capital allocation. Rinzimetostat's value is enhanced by a unique royalty-free license and free darolutamide supply from Bayer, maximizing potential post-approval returns.
2026-07-20 08:30:00
Enozertinib poster presentation to highlight data from an ongoing Phase 1b trial in first-line EGFR atypical NSCLC Rinzimetostat trial-in-progress poster presentation to highlight the ongoing Himalayas-1 Phase 3 study design in patients with mCRPC previously treated with abiraterone Rinzimetostat ePoster to highlight data supporting its potential to enhance AR signaling and restrict lineage plasticity in mCRPC SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, July 20, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing treatments that address mechanisms of therapeutic resistance, today announced three poster presentations at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27, 2026, in Madrid, Spain.
2026-07-14 16:05:00
Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone Entered into a clinical trial collaboration and supply agreement with Bayer to provide darolutamide for Himalayas-1 SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, July 14, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the initiation of the Himalayas-1 global Phase 3 registrational trial in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with abiraterone and announced a clinical trial collaboration and supply agreement with Bayer AG (“Bayer”).
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-07-02 16:30:00
SOUTH SAN FRANCISCO and SAN DIEGO, July 02, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on July 1, 2026 (the “Grant Date”), ORIC granted a total of 44,400 non-qualified stock options and 7,200 restricted stock units to three new non-executive employees who began their employment with ORIC in June 2026. These inducement grants were granted pursuant to the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan, subject to recipient's continued employment or service through each applicable vesting date.
2026-06-09 13:02:14
ORIC Pharmaceuticals, Inc. (ORIC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-06-05 16:30:00
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on June 1, 2026 (the “Grant Date”), ORIC granted a total of 34,800 non-qualified stock options and 5,900 restricted stock units to two new non-executive employees who began their employment with ORIC in May 2026.
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
2026-05-27 16:05:00
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will be participating in the following investor conferences in June:
2026-05-21 16:40:00
NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ORIC Pharmaceuticals, Inc. ("Oric" or the "Company") (NASDAQ: ORIC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Frequently Asked Questions
-
What is the current ORIC Pharmaceuticals, Inc. (ORIC) stock price?
-
ORIC Pharmaceuticals, Inc.(NASDAQ:ORIC) stock price is $12.1 in the last trading session. During the trading session, ORIC stock reached the peak price of $14.93 while $7.23 was the lowest point it dropped to. The percentage change in ORIC stock occurred in the recent session was 11.11% while the dollar amount for the price change in ORIC stock was $1.21.
-
ORIC's industry and sector of operation?
-
The NASDAQ listed ORIC is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ORIC?
-
Scott W. Lowe | Founder & Member of Scientific Advisory Board
Jacob Chacko | President, Chief Executive Officer & Director
Kevin Brodbeck | Chief Technical Officer
Richard A. Heyman | Founder, Independent Chairman & Member of Scientific Advisory Board
Daniel Iazzetti | Vice President & Head of People -
How many employees does ORIC have?
-
Number of ORIC employees currently stands at 104. ORIC operates from 240 East Grand Avenue, South San Francisco, CA 94080, US.
-
Link for ORIC official website?
-
Official Website of ORIC is: https://www.oricpharma.com
-
How do I contact ORIC?
-
ORIC could be contacted at phone #650 388 5600 and can also be accessed through its website. ORIC operates from 240 East Grand Avenue, South San Francisco, CA 94080, US.
-
How many shares of ORIC are traded daily?
-
The average number of ORIC shares traded daily for last 3 months was 1.62M.
-
What is the market cap of ORIC currently?
-
The market value of ORIC currently stands at $1.25B with its latest stock price at $12.1